Zobrazeno 1 - 4
of 4
pro vyhledávání: '"J Thaddeus Beck"'
Publikováno v:
Cancer treatment reviews. 69
Metastatic breast cancer (MBC) is the leading cause of cancer-related morbidity and mortality among women worldwide. Endocrine therapy is the standard of care for the most common subtype of MBC, hormone-receptor positive (HR+), human epidermal growth
Autor:
J. Thaddeus Beck, Lasika Seneviratne, Robert William Sweetman, John A. Glaspy, Navneet Dhillon, Chaitali Singh Nangia, Leon Christopher Hwang, Mark S. Chambers, Jennifer K. Litton, J. Randy Sabo, Hope S. Rugo, Timothy F. Meiller, Timothy J. Pluard, Julio A Peguero, Ingrid A. Mayer
Publikováno v:
The Lancet. Oncology. 18(5)
Summary Background Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and
Autor:
Wei He, Xiaochun Liu, Mariana Chavez-MacGregor, Mario Campone, Shanu Modi, Gilberto Lopes, J. Thaddeus Beck, Michelle Miller, Amy Weise, Brigette B.Y. Ma, Jorge Chaves, Miguel Gil-Gil, Luc Dirix, Aditya Bardia, Faye Su, Jacqueline Vuky, Javier Cortes
Publikováno v:
Cancer Research. 78:CT069-CT069
Background: Preclinical data suggest that combination of endocrine therapy (ET) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and mammalian target of rapamycin inhibitor (mTORi) may overcome prior treatment resistance in hormone receptor-pos
Autor:
Fabrice Andre, J. Thaddeus Beck, José Baselga, Valerie Donnet, Miguel Martín, Giampaolo Tortora, Lars Blumenstein, Giuseppe Curigliano, Laure Charbonnier, Nicola Fazio, C. Wilke
Publikováno v:
Cancer Research. 76:CT061-CT061
Background: PIK3CA (encoding phosphatidylinositol 3-kinase [PI3K] p110α) is frequently altered in cancer, resulting in PI3K/mammalian target of rapamycin (mTOR) pathway activation, and contributing to targeted therapy resistance and disease progress